FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1608609548> ?p ?o ?g. }

• W1608609548 endingPage "169" @default.
• W1608609548 startingPage "168" @default.
• W1608609548 abstract "CRAds are a promising strategy for adenoviral gene therapy of cancer. Although preclinical and the first clinical data with first generation CRAds show good results, more specificity of CRAd replication and an infectivity enhancement for target cells would be desirable. To this end we constructed a novel generation of CRAds specific for ovarian cancer treatment, containing the cox-2 promoter driving different mutations of E1A, combined with an adenovirus type 3 fiber-knob mutation on otherwise type 5 viruses. Two length variants of the cox-2 promoter were used, a shorter clone being more active in and a longer clone being more specific for ovarian cancer cells. The aim of this strategy is to investigate whether a more specific or a more active promoter for CRAds is more advantageous. E1A was used as wild type, as delta24-mutation and as delta2-delta24-mutation, testing the concept of specificity enhancement for cancer cells due to delta-mutations. These mutations inactivate Rb binding and thus allow replication only in cell deficient in the p16-Rb pathway, such as most human cancer cells, including ovarian cancers. Since the adenovirus type 3 receptor seems to be highly overexpressed in ovarian cancer cells resulting in a one to two log infectivity enhancement for these cells, we selected the adenovirus 5/3 chimera approach for enhanced transduction of tumor cells. Six different viruses were constructed, amplified and their constructs verified with PCR and restriction enzymes. The replication of all six viruses was one to two logs improved in cox-2 positive cells and one to two logs reduced in cox-2 negative cells compared to wild type adenovirus. In ovarian cancer cells the replication was improved up to three logs as result of the combination of specific replication in and infectivity enhancement for these cells. In addition, the liver-off phenotype of these viruses was tested with primary normal liver cells. Whereas the wild type virus replicated in and lysed the liver cells, our newly constructed CRAds replicated at least two logs lower than wild type. Further more, the cox-2 driven delta24-CRAds showed stronger oncolysis in ovarian tumor cells than an otherwise identical delta24-CRAd without cox2 promoter. Thus these viruses seem to replicate specifically and amplified in ovarian cancer cells while preserving cox-2 negative and especially liver cells. Therefore these viruses could improve the safety and efficacy profile of adenoviral gene therapy strategies for ovarian cancer." @default.
• W1608609548 created "2016-06-24" @default.
• W1608609548 creator A5010794657 @default.
• W1608609548 creator A5017811626 @default.
• W1608609548 creator A5018878912 @default.
• W1608609548 creator A5022987623 @default.
• W1608609548 creator A5037634356 @default.
• W1608609548 creator A5040557156 @default.
• W1608609548 creator A5051668254 @default.
• W1608609548 creator A5075858446 @default.
• W1608609548 date "2004-05-01" @default.
• W1608609548 modified "2023-09-26" @default.
• W1608609548 title "Novel cox-2 driven infectivity enhanced CRAds for treatment of ovarian cancer" @default.
• W1608609548 doi "https://doi.org/10.1016/j.ymthe.2004.06.358" @default.
• W1608609548 hasPublicationYear "2004" @default.
• W1608609548 type Work @default.
• W1608609548 sameAs 1608609548 @default.
• W1608609548 citedByCount "0" @default.
• W1608609548 crossrefType "journal-article" @default.
• W1608609548 hasAuthorship W1608609548A5010794657 @default.
• W1608609548 hasAuthorship W1608609548A5017811626 @default.
• W1608609548 hasAuthorship W1608609548A5018878912 @default.
• W1608609548 hasAuthorship W1608609548A5022987623 @default.
• W1608609548 hasAuthorship W1608609548A5037634356 @default.
• W1608609548 hasAuthorship W1608609548A5040557156 @default.
• W1608609548 hasAuthorship W1608609548A5051668254 @default.
• W1608609548 hasAuthorship W1608609548A5075858446 @default.
• W1608609548 hasBestOaLocation W16086095481 @default.
• W1608609548 hasConcept C106358424 @default.
• W1608609548 hasConcept C121608353 @default.
• W1608609548 hasConcept C126322002 @default.
• W1608609548 hasConcept C143998085 @default.
• W1608609548 hasConcept C159047783 @default.
• W1608609548 hasConcept C2522874641 @default.
• W1608609548 hasConcept C2780427987 @default.
• W1608609548 hasConcept C502942594 @default.
• W1608609548 hasConcept C71924100 @default.
• W1608609548 hasConceptScore W1608609548C106358424 @default.
• W1608609548 hasConceptScore W1608609548C121608353 @default.
• W1608609548 hasConceptScore W1608609548C126322002 @default.
• W1608609548 hasConceptScore W1608609548C143998085 @default.
• W1608609548 hasConceptScore W1608609548C159047783 @default.
• W1608609548 hasConceptScore W1608609548C2522874641 @default.
• W1608609548 hasConceptScore W1608609548C2780427987 @default.
• W1608609548 hasConceptScore W1608609548C502942594 @default.
• W1608609548 hasConceptScore W1608609548C71924100 @default.
• W1608609548 hasLocation W16086095481 @default.
• W1608609548 hasOpenAccess W1608609548 @default.
• W1608609548 hasPrimaryLocation W16086095481 @default.
• W1608609548 hasRelatedWork W2068614944 @default.
• W1608609548 hasRelatedWork W2069482181 @default.
• W1608609548 hasRelatedWork W2353260778 @default.
• W1608609548 hasRelatedWork W2365364931 @default.
• W1608609548 hasRelatedWork W2418638721 @default.
• W1608609548 hasRelatedWork W3003270674 @default.
• W1608609548 hasRelatedWork W3029973090 @default.
• W1608609548 hasRelatedWork W3034140415 @default.
• W1608609548 hasRelatedWork W3092079481 @default.
• W1608609548 hasRelatedWork W3127795805 @default.
• W1608609548 hasVolume "9" @default.
• W1608609548 isParatext "false" @default.
• W1608609548 isRetracted "false" @default.
• W1608609548 magId "1608609548" @default.
• W1608609548 workType "article" @default.